TROP-2 in NSCLC

CME

TROP-2 Overview in NSCLC: Expression, Significance, and Therapeutic Rationale

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: April 25, 2024

Expiration: April 24, 2025

Narjust Florez
Narjust Florez, MD

Activity

Progress
1 2
Course Completed

References

  1. Calles A, Riess JW, Brahmer JR. Checkpoint blockade in lung cancer with driver mutation: choose the road wisely. Am Soc Clin Oncol Educ Book. 2020;40:372-384.
  2. Hong L, Lewis WE, Nilsson M, et al. Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma. Cancers. 2022;14:3473.
  3. Godoy LA, Chen J, Ma W, et al. Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. Biomark Res. 2023;11:7.
  4. Solomon BJ, Ahn JS, Dziadziuszko, et al. ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA2.
  5. US Food and Drug Administration. FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer. fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer. Accessed April 22, 2024.
  6. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Eng J Med. 2016;375:1823-1833.
  7. Cheng S, Pei R, Li J, et al. Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives. Ann Transl Med. 2021;9:1481.
  8. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592-604.
  9. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. v.4.2024. nccn.org. Accessed April 22, 2024.
  10. Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019;30:839-844.
  11. Paz-Ares L, Ahn M, Lisberg AE, et al. TROPION-Lung05: datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract 1314MO.
  12. Osimertinib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2024.
  13. Amivantamab [prescribing information]. Horsham, PA: Janssen Biotech; 2024.
  14. Targeted Oncology. FDA and Takeda to withdraw mobocertinib for EGFR exon20+ NSCLC. targetedonc.com/view/fda-and-takeda-to-withdraw-mobocertinib-for-egfr-exon20-nsclc. Accessed April 22, 2024.
  15. Drilon A, Camidge R, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Eng J Med. 2024;390:118-131.
  16. Adagrasib [prescribing information]. San Diego, CA: Mirati Therapeutics; 2024.
  17. Sotorasib [prescribing information]. Thousand Oaks, CA: Amgen; 2023.
  18. Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ and Wilmington, DE: Daiichi Sankyo and AstraZeneca Pharmaceuticals; 2024.
  19. Jiang A, Gao X, Zhang D, et al. Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma. Oncol Lett. 2013;6:375-380.
  20. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implication. Genes Cancer. 2015;6:84-105.
  21. Sacituzumab govitecan [prescribing information]. Foster City, CA: Gilead Sciences; 2023.
  22. Liu X, Deng J, Yuan Y, et al. Advances in Trop2-targetd therapy: novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022;239:108296.
  23. Lisberg A, Ahn M, Paz-Ares L, et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA12.
  24. Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor Trop2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017;8:28725-28735.